Hoon D S, Ramshaw I A
Cancer Immunol Immunother. 1985;20(2):175-8. doi: 10.1007/BF00205685.
We have observed that cyclophosphamide (CY) treatment of 13762 mammary adenocarcinoma tumor-bearing rats was found to cause tumor regression. Tumor-bearing animals cured with three low doses of CY were partially immune against IV and SC challenge with a high dose of 13762 cells. This immune protection mechanism in CY-cured animals appears to be a T (Ig-) cell-mediated response. Irradiated rats reconstituted with CY-cured animal spleen cells were also partially protected against IV and SC challenge with 13762 cells, whereas irradiated rats reconstituted with CY-control animal spleen cells were not. In vitro primary and secondary cell-mediated cytotoxic activity of CY-cured spleen cells against target 13762 cells was low. The possible relevance of this tumor-model study is in the understanding of CY-induced tumor immune response and its role in preventing metastases or perhaps recurrent tumor growth.
我们观察到,用环磷酰胺(CY)治疗携带13762乳腺腺癌的大鼠会导致肿瘤消退。用三个低剂量CY治愈的荷瘤动物对高剂量13762细胞的静脉注射和皮下攻击具有部分免疫力。CY治愈动物中的这种免疫保护机制似乎是一种T(Ig-)细胞介导的反应。用CY治愈动物的脾细胞重建的辐照大鼠也对13762细胞的静脉注射和皮下攻击具有部分保护作用,而用CY对照动物的脾细胞重建的辐照大鼠则没有。CY治愈的脾细胞对靶13762细胞的体外初次和二次细胞介导的细胞毒性活性较低。这项肿瘤模型研究的可能意义在于了解CY诱导的肿瘤免疫反应及其在预防转移或可能的复发性肿瘤生长中的作用。